{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:04:52Z","timestamp":1751947492672,"version":"3.41.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Real-world data on Hodgkin lymphoma (HL) treatment and outcomes in Latin America are limited. The B-HOLISTIC study (2010\u20132013) retrospectively assessed treatment patterns and outcomes in patients with stage IIB\u2013IV classical HL receiving frontline chemotherapy (frontline cHL) or relapsed\/refractory HL (RRHL) in regions outside Europe and North America. This subgroup analysis presents findings from patients enrolled from treatment centers in Argentina, Colombia, and Mexico. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Other endpoints included overall survival (OS), best clinical response, and treatment patterns. In Latin America (frontline cHL: 344; RRHL: 92), the most common frontline regimen was ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). In patients with RRHL receiving salvage chemotherapy (92.4%), common regimens were ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) and ICE (ifosfamide, carboplatin, etoposide). Overall, 68.2% of eligible patients with RRHL underwent stem cell transplantation (SCT). Median PFS and OS in the RRHL group was 20.2 and 87\u00a0months, respectively; the 5-year PFS rate was 27.1%. Survival outcomes were improved in patients who underwent SCT than those without SCT. Median PFS and OS in the cHL group were not reached. These data demonstrated that while real-world HL treatment in Latin America was consistent with guidelines during the study period, clinical outcomes were suboptimal compared with developed regions. This emphasizes the need for novel therapies and improved progression to SCT in this patient population. These findings may offer valuable insights and serve as a reference for future studies in this region. ClinicalTrials.gov Identifier: NCT03327571, registered October 31, 2017.<\/jats:p>","DOI":"10.1038\/s41598-025-07704-0","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:18:00Z","timestamp":1751872680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study"],"prefix":"10.1038","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03327571","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alvaro","family":"Hernandez-Caballero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Zerga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rivas-Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-102X","authenticated-orcid":false,"given":"Amado","family":"Karduss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"7704_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3892\/ijo.2023.5509","volume":"62","author":"Y Che","year":"2023","unstructured":"Che, Y. et al. Advances in the treatment of Hodgkin\u2019s lymphoma (Review). Int. J. Oncol. 62, 61. https:\/\/doi.org\/10.3892\/ijo.2023.5509 (2023).","journal-title":"Int. J. Oncol."},{"key":"7704_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40164-022-00360-4","volume":"11","author":"W Hanel","year":"2022","unstructured":"Hanel, W., Herrera, A. F. & Epperla, N. Management of classical Hodgkin lymphoma: A look at up to date evidence and current treatment approaches. Exp. Hematol. Oncol. 11, 108. https:\/\/doi.org\/10.1186\/s40164-022-00360-4 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"7704_CR3","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1182\/blood.2022016274","volume":"139","author":"PWM Johnson","year":"2022","unstructured":"Johnson, P. W. M. Smart salvage treatment for Hodgkin lymphoma. Blood 139, 3563\u20133564. https:\/\/doi.org\/10.1182\/blood.2022016274 (2022).","journal-title":"Blood"},{"key":"7704_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer, D. A. et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, 19\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdy080 (2018).","journal-title":"Ann. Oncol."},{"key":"7704_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.6004\/jnccn.2018.0013","volume":"16","author":"RT Hoppe","year":"2018","unstructured":"Hoppe, R. T. et al. NCCN guidelines insights: Hodgkin lymphoma, version 1.2018. J. Natl. Compr. Cancer Netw. 16, 245\u2013254. https:\/\/doi.org\/10.6004\/jnccn.2018.0013 (2018).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"7704_CR6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","volume":"19","author":"B Sirohi","year":"2008","unstructured":"Sirohi, B. et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma. Ann. Oncol. 19, 1312\u20131319. https:\/\/doi.org\/10.1093\/annonc\/mdn052 (2008).","journal-title":"Ann. Oncol."},{"key":"7704_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08616.x","volume":"153","author":"SD Smith","year":"2011","unstructured":"Smith, S. D. et al. Autologous stem cell transplant for early relapsed\/refractory Hodgkin lymphoma: Results from two transplant centres. Br. J. Haematol. 153, 358\u2013363. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08616.x (2011).","journal-title":"Br. J. Haematol."},{"key":"7704_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail, N. S. et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol. Blood Marrow Transplant. 12, 1065\u20131072. https:\/\/doi.org\/10.1016\/j.bbmt.2006.06.006 (2006).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"7704_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda, A. et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann. Oncol. 16, 625\u2013633. https:\/\/doi.org\/10.1093\/annonc\/mdi119 (2005).","journal-title":"Ann. Oncol."},{"key":"7704_CR10","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.7150\/jca.29308","volume":"10","author":"Z Kr\u00e1l","year":"2019","unstructured":"Kr\u00e1l, Z. et al. Treatment of relapsed\/refractory Hodgkin lymphoma: Real-world data from the Czech Republic and Slovakia. J. Cancer 10, 5041\u20135048. https:\/\/doi.org\/10.7150\/jca.29308 (2019).","journal-title":"J. Cancer"},{"key":"7704_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/10428194.2017.1382698","volume":"59","author":"EA Zagadailov","year":"2018","unstructured":"Zagadailov, E. A. et al. Real-world effectiveness of brentuximab vedotin versus physicians\u2019 choice chemotherapy in patients with relapsed\/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk. Lymphoma 59, 1413\u20131419. https:\/\/doi.org\/10.1080\/10428194.2017.1382698 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"7704_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5\u201329. https:\/\/doi.org\/10.3322\/caac.21254 (2015).","journal-title":"CA Cancer J. Clin."},{"key":"7704_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ijc.28049","volume":"133","author":"L Chatenoud","year":"2013","unstructured":"Chatenoud, L. et al. Hodgkin\u2019s lymphoma mortality in the Americas, 1997\u20132008: Achievements and persistent inadequacies. Int. J. Cancer 133, 687\u2013694. https:\/\/doi.org\/10.1002\/ijc.28049 (2013).","journal-title":"Int. J. Cancer"},{"key":"7704_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bjhh.2017.08.001","volume":"39","author":"JC Jaime-P\u00e9rez","year":"2017","unstructured":"Jaime-P\u00e9rez, J. C. et al. High frequency of primary refractory disease and low progression-free survival rate of Hodgkin\u2019s lymphoma: A decade of experience in a Latin American center. Rev. Bras. Hematol. Hemoter. 39, 325\u2013330. https:\/\/doi.org\/10.1016\/j.bjhh.2017.08.001 (2017).","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"7704_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/10245332.2018.1498166","volume":"23","author":"JC Jaime-P\u00e9rez","year":"2018","unstructured":"Jaime-P\u00e9rez, J. C. et al. Contributions of a regional approach to document hematologic disease in Mexico: A 10-year experience in an open population. Hematology 23, 803\u2013809. https:\/\/doi.org\/10.1080\/10245332.2018.1498166 (2018).","journal-title":"Hematology"},{"key":"7704_CR16","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/jha2.804","volume":"4","author":"I Biasoli","year":"2023","unstructured":"Biasoli, I. et al. Treatment outcomes in classic Hodgkin lymphoma: 5-year update from the Brazilian Hodgkin Lymphoma Registry. EJHaem 4, 1191\u20131195. https:\/\/doi.org\/10.1002\/jha2.804 (2023).","journal-title":"EJHaem"},{"key":"7704_CR17","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1007\/s00277-023-05352-w","volume":"102","author":"L Goveia","year":"2023","unstructured":"Goveia, L. et al. Treatment patterns and outcomes for Hodgkin lymphoma patients aged 60 and older: A report from the Brazilian Prospective Hodgkin Lymphoma Registry. Ann. Hematol. 102, 2815\u20132822. https:\/\/doi.org\/10.1007\/s00277-023-05352-w (2023).","journal-title":"Ann. Hematol."},{"key":"7704_CR18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/ejh.12364","volume":"93","author":"B Andjelic","year":"2014","unstructured":"Andjelic, B. et al. A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: The role of ABVD in daily practice. Eur. J. Haematol. 93, 392\u2013399. https:\/\/doi.org\/10.1111\/ejh.12364 (2014).","journal-title":"Eur. J. Haematol."},{"key":"7704_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799948","volume":"11","author":"D Bhurani","year":"2021","unstructured":"Bhurani, D. et al. Real-world outcomes of Hodgkin lymphoma: A multi-centric registry from India. Front. Oncol. 11, 799948. https:\/\/doi.org\/10.3389\/fonc.2021.799948 (2021).","journal-title":"Front. Oncol."},{"key":"7704_CR20","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3390\/cancers12082166","volume":"12","author":"P Chabay","year":"2020","unstructured":"Chabay, P. et al. Lymphotropic viruses EBV, KSHV and HTLV in Latin America: epidemiology and associated malignancies. A literature-based study by the RIAL-CYTED. Cancers (Basel) 12, 2166. https:\/\/doi.org\/10.3390\/cancers12082166 (2020).","journal-title":"Cancers (Basel)"},{"key":"7704_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bjhh.2017.08.004","volume":"39","author":"RD Gaiolla","year":"2017","unstructured":"Gaiolla, R. D. Hodgkin\u2019s lymphoma in developing countries: Can we go further?. Rev. Bras. Hematol. Hemoter. 39, 299\u2013300. https:\/\/doi.org\/10.1016\/j.bjhh.2017.08.004 (2017).","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"7704_CR22","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","volume":"23","author":"AM Evens","year":"2012","unstructured":"Evens, A. M., Antill\u00f3n, M., Aschebrook-Kilfoy, B. & Chiu, B. C. Racial disparities in Hodgkin\u2019s lymphoma: A comprehensive population-based analysis. Ann. Oncol. 23, 2128\u20132137. https:\/\/doi.org\/10.1093\/annonc\/mdr578 (2012).","journal-title":"Ann. Oncol."},{"key":"7704_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10552-018-1025-0","volume":"29","author":"THM Keegan","year":"2018","unstructured":"Keegan, T. H. M. et al. Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. Cancer Causes Control 29, 551\u2013561. https:\/\/doi.org\/10.1007\/s10552-018-1025-0 (2018).","journal-title":"Cancer Causes Control"},{"key":"7704_CR24","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1158\/1055-9965.Epi-21-0389","volume":"30","author":"H Parada","year":"2021","unstructured":"Parada, H., Vu, A. H., Pinheiro, P. S. & Thompson, C. A. Comparing age at cancer diagnosis between Hispanics and non-Hispanic Whites in the United States. Cancer Epidemiol. Biomark. Prev. 30, 1904\u20131912. https:\/\/doi.org\/10.1158\/1055-9965.Epi-21-0389 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"7704_CR25","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1080\/10428194.2022.2126281","volume":"63","author":"B Ferhanoglu","year":"2022","unstructured":"Ferhanoglu, B. et al. Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: Results from the international, multicenter, retrospective, B-HOLISTIC study. Leuk. Lymphoma 63, 3317\u20133330. https:\/\/doi.org\/10.1080\/10428194.2022.2126281 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"7704_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000491989","volume":"140","author":"PR Colunga-Pedraza","year":"2018","unstructured":"Colunga-Pedraza, P. R., Gomez-Cruz, G. B., Colunga-Pedraza, J. E. & Ruiz-Arg\u00fcelles, G. J. Geographic hematology: Some observations in Mexico. Acta Haematol. 140, 114\u2013120. https:\/\/doi.org\/10.1159\/000491989 (2018).","journal-title":"Acta Haematol."},{"key":"7704_CR27","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/j.canep.2016.07.016","volume":"44","author":"G Kusminsky","year":"2016","unstructured":"Kusminsky, G., Abriata, G., Forman, D. & Sierra, M. S. Hodgkin lymphoma burden in Central and South America. Cancer Epidemiol. 44, S158\u2013S167. https:\/\/doi.org\/10.1016\/j.canep.2016.07.016 (2016).","journal-title":"Cancer Epidemiol."},{"key":"7704_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1200\/JCO.18.01652","volume":"37","author":"JL Biccler","year":"2019","unstructured":"Biccler, J. L. et al. Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: A nordic lymphoma epidemiology group study. J. Clin. Oncol. 37, 703\u2013713. https:\/\/doi.org\/10.1200\/JCO.18.01652 (2019).","journal-title":"J. Clin. Oncol."},{"key":"7704_CR29","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1080\/10428194.2017.1421762","volume":"59","author":"GP Collins","year":"2018","unstructured":"Collins, G. P., Rueda, A., Salles, G., von Tresckow, B. & Zaja, F. Management of Hodgkin lymphoma in the era of brentuximab vedotin: Real-world data from five European countries. Leuk. Lymphoma 59, 2113\u20132120. https:\/\/doi.org\/10.1080\/10428194.2017.1421762 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"7704_CR30","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1634\/theoncologist.2019-0172","volume":"24","author":"GS Guru Murthy","year":"2019","unstructured":"Guru Murthy, G. S., Szabo, A., Hamadani, M., Fenske, T. S. & Shah, N. N. Contemporary outcomes for advanced-stage classical Hodgkin lymphoma in the U.S.: Analysis of surveillance, epidemiology, and end results database. Oncologist 24, 1488\u20131495. https:\/\/doi.org\/10.1634\/theoncologist.2019-0172 (2019).","journal-title":"Oncologist"},{"key":"7704_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100998","volume":"38","author":"S Hewamana","year":"2021","unstructured":"Hewamana, S. et al. Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin lymphoma in Sri Lanka. EClinicalMedicine 38, 100998. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100998 (2021).","journal-title":"EClinicalMedicine"},{"key":"7704_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.5306\/wjco.v12.i9.800","volume":"12","author":"LF Sanchez-Valledor","year":"2021","unstructured":"Sanchez-Valledor, L. F. et al. Long-term results of the treatment of Hodgkin\u2019s lymphoma in a resource-constrained setting: Real-world data from a single center. World J. Clin. Oncol. 12, 800\u2013807. https:\/\/doi.org\/10.5306\/wjco.v12.i9.800 (2021).","journal-title":"World J. Clin. Oncol."},{"key":"7704_CR33","unstructured":"Geneva: World Health Organization. Global Atlas of Medical Devices. https:\/\/apps.who.int\/iris\/handle\/10665\/255181 (2017)."},{"key":"7704_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41375-020-0875-0","volume":"35","author":"J Driessen","year":"2020","unstructured":"Driessen, J. et al. Primary therapy and relative survival in classical Hodgkin lymphoma: A nationwide population-based study in the Netherlands, 1989\u20132017. Leukemia 35, 494\u2013505. https:\/\/doi.org\/10.1038\/s41375-020-0875-0 (2020).","journal-title":"Leukemia"},{"key":"7704_CR35","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","volume":"34","author":"G Hapgood","year":"2016","unstructured":"Hapgood, G. et al. Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J. Clin. Oncol. 34, 2493\u20132500. https:\/\/doi.org\/10.1200\/JCO.2015.65.4194 (2016).","journal-title":"J. Clin. Oncol."},{"key":"7704_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/725219","volume":"2011","author":"P Shenoy","year":"2011","unstructured":"Shenoy, P., Maggioncalda, A., Malik, N. & Flowers, C. R. Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv. Hematol. 2011, 725219. https:\/\/doi.org\/10.1155\/2011\/725219 (2011).","journal-title":"Adv. Hematol."},{"key":"7704_CR37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","volume":"148","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz, C. H. et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br. J. Haematol. 148, 890\u2013897. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08037.x (2010).","journal-title":"Br. J. Haematol."},{"key":"7704_CR38","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","volume":"97","author":"R Devillier","year":"2012","unstructured":"Devillier, R. et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy. Haematologica 97, 1073\u20131079. https:\/\/doi.org\/10.3324\/haematol.2011.056051 (2012).","journal-title":"Haematologica"},{"key":"7704_CR39","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/go.21.00223","volume":"7","author":"A Anampa-Guzm\u00e1n","year":"2021","unstructured":"Anampa-Guzm\u00e1n, A., Acevedo, F., Partridge, A. H., Alfano, C. M. & Nekhlyudov, L. Cancer survivorship in Latin America: Current status and opportunities. JCO Glob. Oncol. 7, 1472\u20131479. https:\/\/doi.org\/10.1200\/go.21.00223 (2021).","journal-title":"JCO Glob. Oncol."},{"key":"7704_CR40","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/s12913-020-05498-7","volume":"20","author":"S Doubova","year":"2020","unstructured":"Doubova, S. et al. Experiences with health care and health-related quality of life of patients with hematologic malignancies in Mexico. BMC Health Serv. Res. 20, 644. https:\/\/doi.org\/10.1186\/s12913-020-05498-7 (2020).","journal-title":"BMC Health Serv. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07704-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:18:04Z","timestamp":1751872684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07704-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7704"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07704-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.H-C. has served as a speaker for Sanofi, Takeda, Janssen, Bristol Myers Squibb, AbbVie, and Roche, is an advisor for Sanofi, Takeda, Bristol Myers Squibb, Celgene, and Janssen, and has received research grants from Janssen, Bristol, Takeda, MSD, AstraZeneca, and Roche. R.S. has received conference fees from AbbVie, Eli Lilly, and Roche. M.Z. has received conference fees from Bristol Myers Squibb, Janssen, Roche, and Takeda; support for attending meetings from Sandoz, Amgen, AbbVie, Teva, and Pint Pharma; honoraria from Takeda, AbbVie, AstraZeneca, Teva, and Sandoz; and has participated on the advisory board for Takeda, Janssen, and Merck. S.R-V. has received honoraria from Roche and serves on the advisory board for Takeda. Z.H. is an employee of Takeda Pharmaceuticals and holds Takeda shares. A.K. has received honoraria from Takeda, Amgen, and Janssen, and serves as a member of a board of directors and advisory committee of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the Declaration of Helsinki and the International Conference on Harmonization Guidelines on Good Clinical Practice and was approved by the relevant Independent Ethics Committee\/Institutional Review Boards at each center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"24197"}}